Cytotheryx Revenue and Competitors
Estimated Revenue & Valuation
- Cytotheryx's estimated annual revenue is currently $2.8M per year.
- Cytotheryx's estimated revenue per employee is $155,000
Employee Data
- Cytotheryx has 18 Employees.
- Cytotheryx grew their employee count by 6% last year.
Cytotheryx's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Business Development | Reveal Email/Phone |
3 | Director Research and Development | Reveal Email/Phone |
4 | Director Operations | Reveal Email/Phone |
5 | Director Business Development | Reveal Email/Phone |
6 | Business Office Manager | Reveal Email/Phone |
7 | Production Manager | Reveal Email/Phone |
Cytotheryx Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 50 | 9% | N/A | N/A |
#2 | $7.4M | 48 | -35% | N/A | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $0.3M | 2 | -91% | N/A | N/A |
#5 | $3.6M | 23 | 5% | N/A | N/A |
#6 | $0.9M | 6 | -33% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $14.7M | 95 | 9% | N/A | N/A |
#9 | $14.7M | 95 | 0% | $20.5M | N/A |
#10 | $27.9M | 144 | 13% | $39.1M | N/A |
What Is Cytotheryx?
Cytotheryx is a biomedical research company focused on the development of a consistent, high-quality source of human hepatocytes (HHCs) and the application of those HHCs for multiple research and clinical applications. HHCs are used in toxicology studies, hepatitis research and transplants, but the limited supply restricts these broader applications. Cytotheryx's foundational science will relieve the restriction and enable applications in liver assist devices, cell and gene therapy, drug delivery and allotransplantation.
keywords:N/AN/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 18 | 6% | N/A |
#2 | $3.5M | 18 | -14% | N/A |
#3 | $35M | 18 | -5% | N/A |
#4 | $3.1M | 18 | -44% | N/A |
#5 | $1.6M | 18 | 6% | N/A |